Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Recruiting · Columbia, Missouri
Always free
Study care at no cost to you
For your time and travel
Many studies pay you back
Most need no insurance or papers
Legal status usually isn't required; we'll tell you each study's requirements
Interpreters available
Ask for your language
Your choice
Voluntary — you can stop anytime
What is this study?
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
It is , overseen by an independent and licensed medical staff.
Read the full clinical description
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Who this study is looking for
In plain language, from the study's own rules. The study team confirms the full details with you — this isn't a final yes or no.
✅ You may be able to join if…
- •People with MASH based on liver biopsy (if done within 12 months of screening) or liver scoring rules described in the study.
- •People with MRI-PDFF showing at least 8% liver fat within 4 weeks of the baseline visit.
- •People who have at least 1 metabolic syndrome risk feature listed in the study (including type 2 diabetes, high blood sugar, high blood pressure, high triglycerides, low HDL, or overweight/obesity with waist size rules).
- •People whose AST blood test is high enough for their sex (AST >17 U/L for women; AST >20 U/L for men, unless they have an eligible biopsy result).
🚫 You may not be able to join if…
- •People in another MASH or weight-loss clinical trial (including GLP-1 receptor agonists) within the last 3 months.
- •People in any other clinical trial within the last 3 months or within 5 half-lives of the study treatment (whichever is longer).
- •Women who are pregnant, planning pregnancy, or breastfeeding.
- •People with BMI under 18 kg/m² or over 45 kg/m².
- •People who drink too much alcohol (more than 20 g/day for women or 30 g/day for men) or who have certain other liver diseases (hepatitis B/C, autoimmune hepatitis, primary biliary cholangitis, Wilson’s disease).
- •People with known or suspected cirrhosis or signs of liver becoming “decompensated.”
- •People with recent heart attack, unstable angina, or stroke (within 3 months).
- •People with uncontrolled high blood pressure (systolic >160 or diastolic >100).
Are you a good fit?
Simplified highlights. The study team always confirms the full details with you.
- ✓Adults roughly 18–75
- ✓A BMI around 25 or higher
- ✓Have Obesity / overweight or Type 2 diabetes or Fatty liver disease (NASH/MASH) or High blood pressure
- !Some conditions may not be a fit: Heart / cardiovascular disease
- !Not for people who are pregnant or breastfeeding
- !May require a break from current GLP-1 medications
What to expect, step by step
- 1
Usually a few weeks
The study team checks whether the study is a good fit for you, with a visit and sometimes lab tests. You can ask any questions before deciding.
- 2
Treatment
If you join and choose to continue, you receive the study treatment and are watched closely by medical staff.
- 3
Follow-up
After treatment, the team checks on your health and confirms the visit schedule with you. You can leave the study at any point.
Has this treatment been tested before?
This is an early-stage study. The treatment has gone through laboratory and preliminary testing before being studied in people here.
What you need to know before you apply
What is this study testing?+
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Is it safe? Who makes sure of that?+
This is an early study (Phase 1), focused mostly on safety. Every study is reviewed and monitored by an independent ethics board (called an IRB) whose job is to protect participants, and care is overseen by licensed medical staff. You'll be told the known risks before you agree to anything, and you can stop at any time.
Will I get a placebo instead of the real treatment?+
Some studies compare a treatment against a placebo (an inactive version), and some don't. If this one does, the study team will explain your chances of receiving the active treatment before you decide. Nothing is hidden from you.
I take a GLP-1 medication (like Ozempic or Wegovy). Can I still join?+
Maybe. This study may ask you to pause certain weight or diabetes medications for a period of time (a 'washout') before joining, or it may be looking for people not currently on them. The coordinator will review your medications with you — don't stop any medication on your own.
Does it cost anything? Will I be paid?+
The study treatment and study-related visits are provided at no cost to you. This study may also compensate you for your time and travel — the team will tell you the amount before you join. You should never be asked to pay to take part.
Do I need insurance? Will anyone ask about my immigration status?+
No. You do not need health insurance to take part in a research study, and you will not be asked about your immigration status to join. Taking part is about whether you're a medical fit for the study.
What if English isn't my first language?+
You have the right to understand everything before you agree. Study sites can often provide materials or an interpreter in your language — you can ask the coordinator for one.
Is my information private?+
Yes. Your health information is only shared with the study sites you choose to be contacted by, and only to help match and enroll you. It is never sold, and you can ask us to delete it at any time.
Source: ClinicalTrials.gov · NCT06947304 · Locations: Missouri